Form 4: Moderna Director Elizabeth E. Tallett Acquires Stock Options

Director Elizabeth E. Tallett acquired stock options in Moderna, Inc. on May 6, 2024.

Summary

• On May 6, 2024, Elizabeth E. Tallett, a director of Moderna, Inc., acquired 7,557 stock options at an exercise price of $122.13.
• These options will vest and become exercisable on the earlier of May 6, 2025, or Moderna's next Annual Meeting of Stockholders, contingent upon continued service.
• Following the transaction, Tallett directly owns 7,557 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The document reflects a routine transaction (stock option grant) and doesn't contain overtly positive or negative information. It's a neutral event from an investment perspective.

Positives

• A director's acquisition of stock options can be seen as a positive signal, indicating confidence in the company's future performance.

Future Outlook

The vesting of the options is contingent upon continued service, suggesting an expectation of Tallett's continued involvement with Moderna.

Industry Context

Director stock option grants are a common practice in the biotechnology industry to align management's interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants to directors are a standard component of compensation packages in publicly traded companies, particularly in the biotech sector.
• Companies like Pfizer, BioNTech, and Johnson & Johnson also utilize stock options as part of their director compensation plans.
• The size and vesting schedule of these grants are typically benchmarked against peer companies to ensure competitiveness and alignment with performance goals.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment, as it signals confidence from a director.

Key Dates